Tristel plc (AIM:TSTL)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 191.73M |
| Revenue (ttm) | 46.46M |
| Net Income (ttm) | 6.64M |
| Shares Out | 47.93M |
| EPS (ttm) | 0.14 |
| PE Ratio | 28.92 |
| Forward PE | 23.18 |
| Dividend | 0.14 (3.55%) |
| Ex-Dividend Date | Nov 27, 2025 |
| Volume | 52,079 |
| Average Volume | 85,488 |
| Open | 410.00 |
| Previous Close | 410.00 |
| Day's Range | 400.00 - 415.00 |
| 52-Week Range | 260.00 - 445.00 |
| Beta | 0.25 |
| RSI | 42.08 |
| Earnings Date | Mar 2, 2026 |
About Tristel
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surfaces, dosing system, airstel, enzystel, DOK, pre-clean wipes, rinse wip... [Read more]
Financial Performance
In fiscal year 2025, Tristel's revenue was 46.46 million, an increase of 10.80% compared to the previous year's 41.93 million. Earnings were 6.64 million, an increase of 2.33%.
Financial StatementsNews
Full Year 2025 Tristel PLC Online Investor presentation Transcript
Full Year 2025 Tristel PLC Online Investor presentation Transcript
Tristel plc (TSNLF) Q4 2025 Earnings Call Transcript
Half Year 2025 Tristel PLC In-person Presentation Transcript
Half Year 2025 Tristel PLC In-person Presentation Transcript
Tristel revenue up as it targets opportunities in high-growth markets
Tristel sees strong performance as it continues to focus on opening up new high-growth overseas markets under new CEO Matt Sassone
Full Year 2024 Tristel PLC Analyst briefing Transcript
Full Year 2024 Tristel PLC Analyst briefing Transcript